SHANGHAI and BEIJING, February 25, 2021 – BioDuro-Sundia has received the award “Excellent Partner 2020” from BioFront Drug Discovery Innovation Center, in recognition of the excellent services and project contributions by the Chemistry and Biology teams within the BioDuro-Sundia Drug Discovery Unit.
“BioDuro-Sundia has deep experience in drug discovery and very responsive project management. In both the communications between project teams on both sides, and the coordinations of whole project studies, BioDuro-Sundia and BioFront have interacted seamlessly,” said Dr. Zheng Huang, Head of Drug Discovery at BioFront, who visited BioDuro-Sundia Shanghai site and presented the award to the Biology team. “In 2021, we will expand our collaboration in both small molecules and biologics drug discovery. We believe that we will have more comprehensive collaborations in the future.”
BioDuro-Sundia provides drug discovery services to BioFront in multiple areas at multiple research sites. The two companies have been partners for many years, and have steadily worked together to advance BioFront’s pipeline.
“We have deep and comprehensive collaborations across multiple disciplines including chemistry, in vitro biology, in vivo pharmacology and potentially biologics,” said Dr. Xiang Li Head of Integrated Biology at BioDuro-Sundia. “For instance, BioFront has just committed to work with us in additional in vivo pharmacology studies.”
The chemistry project recognized in the award was led by Dr. Shao Ning, Head of Chemistry and Dr. Qiao Xiangchen, Director of Chemistry at BioDuro-Sundia Beijing. The biology project was led by Dr. Teng Lin, Director of Discovery Biology and Dr. Guo Yanchun, Senior Group Leader of Discovery Biology in Shanghai. The teams worked closely together and expanded quickly, producing many new compounds, followed by high quality biological functional studies, yielding rich research data and reports for BioFront.
“The partnership between BioFront and BioDuro-Sundia is a perfect example for our integrated services. We are exploring and trying to establish new collaborations with other partners, look forward to provide high quality services to different clients,” said Lisa Ren, Head of Business Development, BioDuro-Sundia, China/APAC. “BioDuro-Sundia always cherishes the principle of ‘client first’, and our ‘one-stop-shop’ operation helps biopharma partners around the globe to significantly accelerate discovery and de-risk development to realize high value outcomes.”
BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product. The company is the industry’s third largest, with major operations in China and the US—featuring more than 2,000 employees and 10 global sites.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The company has research sites, as well as GMP manufacturing facilities in both China and the US. The one-stop-shop operation helps biopharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes.
BioDuro-Sundia investment is led by Advent International, with backing from Bridgewest Business Group.
For more information, visit:
About BioFront Drug Discovery Innovation Center
BioFront is a biotech company founded in 2018 by senior drug discovery executives and experts from Eli Lilly and Merck.